ArticleEJIFCC2026
Rethinking the Limit of Detection for Serum Ethanol: Evidence from a Clinical Laboratory.
Article in EJIFCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethanol is a widely consumed psychoactive substance. Serum concentrations above 100 mg/dL can cause cognitive impairment and confusion, while levels exceeding 300 mg/dL may be fatal. Thus, rapid and accurate determination of blood ethanol concentration is crucial for diagnosing and managing acute intoxication. Ethanol measurement also has important legal implications, such as in traffic accidents or criminal proceedings. Gas Chromatography-Mass Spectrometry (GC-MS) is the reference method for ethanol determination due to its accuracy and specificity. In routine clinical laboratories, however, ethanol quantification is usually performed using enzymatic spectrophotometric assays. Alcohol dehydrogenase (ADH) oxidizes ethanol to acetaldehyde with NAD as coenzyme, which is simultaneously reduced to NADH. The increase in NADH absorbance at 340 nm allows indirect quantification of ethanol. Although analytical characterization and method optimization are the manufacturers' responsibilities, literature indicates these processes are not standardized, and specific procedures are generally not disclosed. Consequently, clinical laboratories may need to verify these values, particularly during implementation of new methods, internal validation, or when analytical results conflict with clinical presentation. We report four cases in our laboratory with positive ethanol results of 11-14 mg/dL that, after reprocessing, were reported as "not detected". This highlights the need to determine the smallest analyte quantity detectable with certainty, commonly expressed as the limit of detection (LoD).
Indexed as
Identifiers
42730046PMC13563536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.